Neuron specific enolase in small cell lung cancer. Clinical and biochemical evaluation

Danish Medical Bulletin

Volumn 46, Issue 1, 1999, Pages 1-12

  Jørgensen, Lone G M ^a,b,c  

^a FINSEN LABORATORY   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

NEURON SPECIFIC ENOLASE;

ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME ASSAY; HUMAN; LUNG SMALL CELL CANCER;

ANIMALS; CARCINOMA, SMALL CELL; HUMANS; LUNG NEOPLASMS; PHOSPHOPYRUVATE HYDRATASE; TUMOR MARKERS, BIOLOGICAL;

EID: 0032995710     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (190)

1. Jørgensen L, Østerlind K, Hansen HH, Cooper EH. The prognostic influence of neuron specific enolase in small cell lung cancer. Br J Cancer; 1988: 58, 805-7.
2. Jørgensen L, Hansen HH, Cooper EH. Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer. Eur J Cancer Clin Oncol; 1989: 25, 123-8.
3. Jørgensen LGM, Hirsch FR, Skov BG, Østerlind K, Cooper EH, Larsson LI. Occurrence of neuron specific enolase in tumour tissue and serum in small cell lung cancer. Br J Cancer; 1991: 63, 151-3.
4. Jørgensen LGM, Østerlind K, Hansen HH, Cooper EH. Serum neuron specific enolase (NSE) is a determinant of response duration in small cell lung cancer (SCLC). Br J Cancer; 1992: 66, 594-8.
5. Jørgensen LGM, Østerlind K, Hansen HH, Cooper EH. Neuron specific enolase (NSE) in progressive small cell lung cancer (SCLC). Br J Cancer; 1994: 70, 759-61.
6. Jørgensen LGM, Østerlind K, Genollá J, Gomm SA, Hernández JH, Johnson PWM, Løber J, Splinter TAW, Szturmowicz M. Serum neuron specific enolase (S-NSE) and the prognosis in small cell lung cancer (SCLC): A combined multivariable analysis on data from nine centres. Br J Cancer; 1996: 74, 463-7.
7. Jørgensen LGM, Løber J, Carlsen NLT, Momsen G, Hirsch FR. Serum neuron specific enolase (S-NSE) reference interval evaluation by time-resolved immunofluorometry compared with a radioimmunoassay. Clin Chim Acta; 1996: 249, 77-91.
8. Adewole IF, Newlands ES. Neuron-specific enolase (NSE) as a tumour marker and comparative evaluation with carcinoembryonic antigen (CEA) in small-cell lung cancer. Med Oncol Tumor Pharmacother 1987; 4: 11-5.
9. Albain, KS, Crowley JJ, Leblanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: An analysis of the 2580-patient Southwest Oncology Group data base. J Clin Oncol 1990; 8: 1563-74.
10. Altman DG. Categorising continuous variables. Br J Cancer 1991; 64: 975.
11. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996: 14: 2843-77.
12. Amerlite Diagnostics Ltd. CEA RIA kit, Code IMB 4511, 1992.
13. Andersen PK, Waeth M. Statistisk analyse af overlevelsesdata. FADL, Copenhagen 1984.
14. Andersen PK. Survival analysis 1982-1991: The second decade of the proportional hazards regression model. Stat Med 1991; 10: 1931-41.
15. Andoh M, Gemma A, Takenaka K, Hisakatsu S, Yamada K, Usuki J, Hasegawa K, Sakonji M, Kudoh S, Tsuboi E, et al. Serum neuron specific enolase level as a prognostic factor in non-small cell lung cancer. Intern Med 1994; 33: 271-6.
16. Akoun GM, Scarna HM, Milleron BJ, Bénichou MP, Herman DP. Serum neuron-specific enolase. A marker for disease extent and respon-se to therapy for small-cell lung cancer. Chest 1985; 87; 39-43.
17. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij. Topotecan, a new active drug in the second-line treatment of small cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997; 15: 2090-6.
18. Ariyoshi Y, Kato K, Ishiguro Y, Ota K, Sato T, Suchi T. Evalua-tion of serum neuron specific enolase as a tumor marker for carcinoma of the lung. Gann 1983; 74: 219-225.
19. Arvan DA. Tumor cell heterogeneity: an overview. Clin Chem Acta 1992; 206: 3-7.
20. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners C. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989; 57: 327-34.
21. Bergh J, Esscher T, Steinholtz L, Nilsson K, Påhlman S. Immuno-cytochemical demonstration of neuron-specific enolase (NSE) in human lung cancers. Am J Clin Path 1985; 84: 1-7.
22. Bergman B, Brezicka FT, Engstrom CP, Larsson S. Clinical usefulness of serum assays of neuron specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer. Eur J Cancer 1993; 29A: 198-202.
23. Biran H, Feld R, Malkin A. Circulating arginine-vasopressin, Calcitonin, carcinoembryonic antigen, neuron specific enolase, and beta-2-microglobulin fluctuations during combined modality induction therapy for small cell bronchogenic carcinoma. Tumor Biol 1991; 12: 131-7.
24. BMDP Statistical Software (Dixon WJ, ed.). University of California Press, Berkley, 1981 & 1992.
25. Bork E, Hansen M, Ursdal P, Paus E, Holst JJ, Schifter S, Fenger M, Engbaek F. Early detection of response in small cell bronchogenic carcinoma by changes in serum concentrations of creatine kinase, neuron specific enolase, calcitonin, ACTH, serotonin and gastrin releasing peptide. Eur J Cancer Clin Oncol 1988; 24: 1033-1038.
26. Brambilla E, Veale D, Moro D, Morel F, Dubois F, Brambilla C. Neuroendocrine phenotype in lung cancers. Comparison of immunohistochemistry with biochemical determination of enolase isoenzymes. Am J Clin Pathol 1992; 98: 88-97.
27. Broers JLV, Ramaekers FCS. Differentiation markers for lung cancer sub types. A comparative study of their expression in vivo and in vitro. Int J Cancer 1994; 8: 134-7.
28. Brown WH. A case of pluriglandular syndrome: diabetes of bearded women. Lancet 1928; 2: 1022-3.
29. Buamah PK, Crake SR, Smedley HM, Bodger WAH, Skillen AW. Neuron specific enolase during chemotherapy of small cell lung cancer. J Surg Oncol 1990; 44: 1-4.
30. Bunn PA Jr. Current therapy for small cell lung cancer. Sem Oncol 1996; 23 supp 16: 1-4.
31. Burghuber OC, Worofka B, Schernthaner G, Vetter N, Neumann M, Dudczak R, Kuzmits R. Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer. Cancer 1990; 65: 1386-90.
32. Caldas C. Molecular staging of cancer: is it time. Lancet 1997; 350: 231.
33. Capella C, Heitz PU, Hoefler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Archiv 1995; 425: 547-60.
34. Carlei F, Polak JM. Antibodies to neuron specific enolase for the delineation of the entire diffuse neuroendocrine system in health and disease. Semin Diag Pathol 1984; 1: 59-70.
35. Carney DN, Marangos PJ, Ihde DC, Bunn PJ, Cohen MH, Minna JD. Serum neuron-specific enolase: A marker for disease extent and response to therapy of small-cell lung cancer. Lancet 1982; i: 583-5.
36. Cattoretti G, Pileri S, Parravicini C, Becker MHG, Poggi S, Bifulco C, Key G, D'Amato L, Sabattini E, Feudale E, Reynolds F, Gerdes J, Rilke F. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 1993; 171: 83-98.
37. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small cell lung cancer patients. Int J Cancer 1987; 39: 146-9.
38. Cohen MH, Makuch R, Johnston-Early A, Ihde DC, Bunn PA, Fossieck BE jr., Minna JD. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep 1981; 65: 187-95.
39. Collazos J, Genolla J, Ruibal ATI. Neuron specific enolase concentrations in serum in benign liver diseases. Clin Chem 1991; 37: 579-81.
40. Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Physiology. Scand J Clin Lab Invest 1973; 2: 291-306.
41. Cooper EH, Splinter TAW, Brown DA, Muers MF, Peake MD, Pearson SL. Evaluation of a radioimmunoassay for neuron specific enolase in small cell lung cancer. Br J Cancer 1985; 52: 333-8.
42. Cooper EH. Neuron-specififc enolase. International Journal of Biological Markers 1994; 9: 205-10.
43. Cox DR. Regression models and life-tables. J Roy Stat Soc 1972; 34: 187-220.
44. Cunningham RT, Morrow JI, Johnston CF, Buchanan KD. Serum neurone-specific enolase concentrations in patients with neurological disorders. Clin Chim Acta 1994; 230: 117-24.
45. DELFIA NSE kit. Time-resolved fluoroimmunoassay kit. For "in vitro" diagnostic use. Wallac, Finland, 1994.
46. Diez M, Torres A, Ortega L, Maestro M, Hernando F, Gomez A, Picardo A, Granell J, Balibrea JL. Value of serum neuron specific enolase in non-small cell lung cancer. Oncology 1993; 50: 127-31.
47. Drivsholm L, Vangsted A, Pallesen T, Hansen M, Dombernowsky P, Hirsch F, Hansen HH. Fucosyl-GM1 in small cell lung cancer. A comparison with the tumour marker neuron specific enolase. Ann Oncol 1994; 5: 623-6.
48. Duncan ME, McAleese SM, Booth NA, Melvin WT, Fothergill JE. A simple enzyme linked immunosorbent assay (ELISA) for the neuron specific gamma isozyme of human enolase (NSE) using monoclonal antibodies raised against synthetic peptides corresponding to isozyme sequence differences. J Immunol Methods 1992; 151: 227-36.
49. Ebert W, Hug G, Stabrey A, Bülzebruck H. Neuron specifische enolase (NSE) als marker für das kleinzellige Bronchialkarzinom. Tumordiagn u Ther 1990; 11: 60-7.
50. Ebert W, Dienemann H, Fateh-Moghadam A, Scheulen M, Konietzko N, Schleich T, Bombardieri E. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Eur J Clin Chem Clin Biochem 1994; 32: 189-99.
51. Ebert W, Muley TH, Drings P. Does the assessment of serum markers in patients with lung cancer aid in the clinical dicision making process? Anti-cancer Res 1996; 16: 2161-8.
52. Elliott JA, Østerlind K, Hirsch FR, Hansen HH. Metastatic pattern in small cell lung cancer: Correlation of autopsy findings with clinical parameters in 537 patients. J Clin Oncol 1987; 5: 246-54.
53. Erlandson RA, Nesland JM. Tumors of the endocrine/neuroendocrine system: An overview. Ultrastruct Pathol 1994; 18: 149-70.
54. Esscher T, Steinholtz L, Bergh J, Nou E, Nilsson K, Påhlman S. Neuron specific enolase: a useful diagnostic serum marker for small cell carcinoma of the lung. Thorax 1985; 40: 85-90.
55. Esscher T, Bergh J, Steinholtz L, Nöu E, Kenneth Nilsson, Sven Påhlman. Neuron-specific enolase in small cell carcinoma of the lung: The value of combined immunocytochemistry and serum determination. Anticancer Res 1989; 9: 1717-20.
56. van der Gaast A, van putten WLJ, Ossteron R, Cozijnsen M, Hoekstra R, Splinter TAW.Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer. Br J Cancer 1991; 64: 369-72.
57. Ganz PA, Baras M, Ma PY, Elashoff RM. Monitoring the therapy of lung cancer with alpha-1-acid glycoprotein. Cancer Res 1984; 44: 5415-21.
58. Ganz PA, Ma PY, Wang H-J, Elashoff RW. Evaluation of three biochemical markers for serially monitoring the therapy of small cell lung cancer. J Clin Oncol 1987; 5: 472-9.
59. Gerbitz KD, Summer J, Schumacher I, Arnold H, Kraft A, Mross K. Enolase isoenzymes as tumour markers. J Clin Chem Clin Biochem 1986; 24: 1009-16.
60. Gilpin DA, Hsieh C-C, Kuninger DT, Herndon DN, Papaconstantinou J. Regulation of the acute phase response genes alpha-1-acid glycoprotein and alpha-1-antitrypsin correlates with sensitivity to thermal injury. Surgery 1996; 119: 664-73.
61. Ginsberg RJ, Kris MG, Armstrong JG In DeVita, Hellman VTS & Rosenberg SA, Eds, Cancer: Principles and practice of oncology, JB Lippincot, Philadelphia 1993: 673-722.
62. Giovanella L, Piantanida R, Ceriani L, Bandera M, Novario R, Bianchi L, Roncari G. Immunoassay of neuron specific enolase (NSE) and serum fragments of cytokeratin 19(CYFRA 21.1) as tumor markers in small cell lung cancer: clinical evaluation and biological hypothesis. Int J Biol Markers 1997; 12: 22-6.
63. Gomm SA, Keevil BG, Thatcher N, Hastleton PS, Swindell RS. The value of tumour markers in lung cancer. Br J Cancer 1988; 58: 797-804.
64. Gosney JR. Neuroendocrine cell populations in postnatal human lungs: minimal variation from childhood to old age. Anat Rec 1993; 236: 177-80.
65. Goss GD, Dahrouge S, Lochrin CA. Recent advances in the treatment of non-small cell lung cancer. Anti Cancer Drugs 1996; 7: 363-85.
66. Gronowitz JS, Bergstroøm R, NouE, Påhlman S, Brodin O, Nilsson S, Kallander FR. Clinical and serological markers of stage and prognosis in small cell lung cancer. Cancer 1990; 66: 722-32.
67. Hansen HH. Management of small-cell cancer of the lung. Lancet 1992; 339: 846-9.
68. Hansen HH, Perry M, Arriagada R, Chastang C, Drings P, Østerlind K, Parmar M, Pignon JP, Thatcher N. Treatment evaluation. Lung Cancer 1994; 10: 7-9.
69. Harding M, McAllister J, Hulks G, Vernon D, Monie R, Paul J, Kaye SB. Neuron specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance?. Br J Cancer 1990; 61: 605-7.
70. Hattori T, Ohsawa K, Mizuno Y, Kato K, Kohsaka S. Synthetic peptide corresponding to 30 amino acids of the C-terminal of neuron-specific enolase promotes survival of neocortical neurons in culture. Biochem Biophys Res Comm 1994; 202: 25-30.
71. Hattori T, Takei N, Mizuno Y, Kato K, Kohsaka-S. Neurotrophic and neuro-protective effects of neuron-specific enolase on cultured neurons from embryonic rat brain. Neurosci-Res. 1995; 21: 191-8.
72. Havemann K, Holle R, Gropp C. Prospective multicenter study of hormone markers in small cell lung cancer. Recent Res Cancer Res 1985; 99: 194-208.
73. Hemmilä I, Dakubu S, Mukkala VM, Siitari H, Lövgren T. Europium as a label in time-resolved immunofluororometric assays. Anal Biochem 1984; 137: 335-43
74. Hirsch FR, Matthews MJ, Aisner S, Campobasso O, Elema JD, Gazdar AF, Mackay B, Nasiell M, Shimosato Y, Steele RH, Yesner R, Zettergren L. Histopathologic classification of small cell lung cancer. Cancer 1988a; 62: 973-7.
75. Hirsch FR, Sehested M, Francis D, Larsson L-I. Neuron specific enolase and chromogranin in the histopathological diagnosis of lung cancer. Lung Cancer 1988b; 3: 32.
76. Hirsch FR, Østerlind K, Jensen LI, Thomsen C, Peters K, Jensen F, Hansen HH. The impact of abdominal computerized tomography on the pretreatment staging and prognosis of small cell lung cancer. Ann Oncol 1992; 3: 469-74.
77. Hyltoft Petersen P, Blaabjerg O. Reference intervals for plasma proteins In Hyltoft Petersen P, Blaabjerg O, Irjala K (Eds.) Assessing quality in measurements of plasma proteins. Lasse Helle Ltd. Print, Helsinki, Finland 1994: 117-123 (ISBN 951-47-9814-7).
78. Ihde DC, Makuch RW, Carney DN, Bunn PA, Cohen MH, Matthews MJ, Minna JD. Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy. Am Rev Respir Dis 1981; 123: 500-7.
79. Jacobs EL, Haskell CM. Clinical use of tumor markers in oncology. Curr Probl Cancer 1991; 15: 299-360.
80. Jaques G, Bepler G, Holle R, Wolf M, Hannich T, Gropp C, Havemann K. Prognostic value of pretreatment carcinoembryonic antigen, neuron specific enolase, and creatine kinase-BB levels in sera of patients with small cell lung cancer. Cancer 1988; 62: 125-34.
81. Jaques G, Auerbach B, Pritsch M, Wolf M, Madry N, Havemann K. Evaluation of serum neural cell adhesion molecule as a new tumor marker in small cell lung cancer. Cancer 1993; 72: 418-25.
82. Jarvisalo J, Hakama M, Knekt P, Stenman UH, Leino A, Teppo L, Maatela J, Aromaa A. Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening. Cancer 1993; 71: 1982-8.
83. Jensen PB. Differential sensitivity patterns in small cell lung cancer cell lines: detection and circumvention of resistance to topoisomerase II targeting drugs. Lægeforeningens forlag, Copenhagen, 1994.
84. Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M. In vitro cross resistance and collateral sensitivity in seven resistant small cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br J Cancer 1997; 75: 869-77.
85. Jereczek B, Jassem J, Karnicka Mlodkowska H, Badzio A, Mos Antikowiak R, Szczepek B, Chojak E, Dziadziusko R, Lisowska B, Malak K. Autopsy findings in small cell lung cancer. Neoplasma (Bratislava) 1996; 43: 133-7.
86. Johnson DH, Marangos PJ, Forbes JT, Hainsworth JD, Van-Welch R, Hande KR, Greco FA. Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung. Cancer Res. 1984; 44: 5409-14.
87. Johnson DH. Future directions in the management of small cell lung cancer. Lung Cancer 1995; 12 Suppl: 71-5.
88. Johnson PWM, Joel SP, Love S, Butcher M, Pandian MR, Squires L, Wrigley PFM, Slevin ML. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer 1993; 67: 760-6.
89. Jørgensen LGM, Østerlind K, Gomm SA, Hernández JR, Johnson PWM, Løber J, Splinter TAW, Szturmowicz M. Tumour marker aided discrimination between disease stages in small cell lung cancer (SCLC). J Tumor Marker Oncol 1996a; 11(4): 7-14.
90. Jørgensen LGM, Böttcher SG, Christensen ES, Lundbye-Christensen S, Winkel P. Monitoring small cell lung cancer ny serum neuron specific enolase (S-NSE) analyses using dynamic linear models. J Tumor Marker Oncol 1996b; 11(4): 15-21.
91. Kakari S, Stringou E, Toumbis M, Ferderigos AS, Poulaki E, Chondros K, Dema A, Kotsovoulou V, Pavlidis N. Five tumor markers in lung cancer: Significance of total and "lipid"-bound sialic acid. Anticancer Res 1991; 11: 2107-10.
92. Klavins JV. Tumor markers, clinical and laboratory studies. Alan r. Liss, Inc., New York, 1985 (ISBN 0-8451-0248-6).
93. Kristjansen PE, Østerlind K, Hansen M. Detection of bone marrow relapse in patients with small cell carcinoma of the lung. Cancer 1986; 58: 2538-41.
94. Larsson L-I. Immunocytochemistry. Theory and practice. CRC Press: Boca Raton, Florida 1988.
95. Lassen U, Osterlind K, Hansen M, Dombernowsky P, Berg-man B, Hansen HH. Long-term survival in small-cell lung cancer: Posttreat-ment characteristics in patient surviving 5 to 18+ years: An analysis of 1,714 consecutive patients. Journal of Clinical Oncology 1995; 13: 1215-20.
96. Lassen U, Kristjansen PEG, Østerlind K, Bergman B, Sigsgaard TC, Hirsch FR, Hansen M, Dombernowsky P, Hansen HH. Superiority of cisplatin or carboplatin in combination with tenoposide and vincristine in the induction chemotherapy of small cell lung cancer. A randomized trial with 5 years follow up. Ann Oncol 1996; 7: 365-71.
97. Lebioda L, Stec B. Mapping of isozymic differences in enolase. Int J Biol Macromol 1991a; 13: 97-100.
98. Lebioda L, Stec B, Brewer JM, Tykarska E. Inhibition of enolase: the crystal structures of enolase-Ca2(+)-2-phosphoglycerate and enolase-Zn2(+)-phosphoglycolate complexes at 2.2-A resolution. Biochemistry 1991b; 30: 2823-7.
99. Ledermann JA. Serum neuron specific enolase and other neuroendocrine markers in lung cancer. Eur J Cancer 1994; 30: 576-7.
100. Lee J, Jones JJ, Barraclough MA. Inappropriate secretion of vasopressin. Lancet 1964; 2: 792-3.
101. Lee ME, Nowak T. Metal ion specificity at the catalytic site of yeast enolase. Biochemistry 1992; 31: 2172-80.
102. Liippo KK, Terho T. Concomitant monitoring of serum neuron-specific enolase and creatine kinase BB in small cell lung cancer. Acta Oncol 1991; 30: 321-4.
103. Loy TS, Darkow GVD, Quesenberry JT. Immunostaining in the diagnosis of pulmonary neuroendocrine carcinomas. An immunohistochemical study with ultrastructurel correlation. Am J Surg Pathol. 1995; 19: 173-82.
104. Marangos PJ, Schmechel DE. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Ann Rev Neurosci 1987; 10: 269-95.
105. Mercer DW. Serum isoenzymes in cancer diagnosis and management. Immunol Ser 1990; 53: 613-29.
106. Mizushima Y, Tsuji H, Izumi S, Hirata H, Kin Y, Kawasaki A, Matsui S, Yano S. Clinical evaluation of five tumor marker assay in patients with lung cancer. Anticancer Res 1991; 11: 91-6
107. Momsen G, Jørgensen LGM. A multivariate control system for quality control of immunofluorometric assay for serum neuron specific enolase (SNSE). J Tumor Marker Oncol 1996; 11(4): 35-48.
108. Moss DW. Physiochemical and pathophysiological factors in the release of membrane-bound alkaline phosphatase from cells. Clin Chim Acta 1997; 257: 133-40.
109. Müller LC, Gasser R, Huber H, Klingler A, Salzer GM. Neuron specific enolase (NSE) in small-cell lung cancer: longitudinal tumor marker evaluation. Lung Cancer 1992; 8: 29-36.
110. Nitta T, Fukuoka M, Masuda N, Kusunoki Y, Matsui K, Kudoh S, Hirashima T, Yana T, Itoh K, Takada M. Significance of serum neuron-specific enolase as a predictor of relapse of small cell lung cancer. Japanese Journal of Clinical Oncology 1995; 25: 179-183.
111. Non small cell lung cancer collaborative group. BMJ 1995; 311: 899-909.
112. Nou E, Steinholtz L, Bergh J, Nilsson K, Pahlman S. Neuron specific enolase as a follow up marker in small cell bronchial carcinoma: A prospective study in an unselected series. Cancer 1990; 65: 1380-5.
113. Ohwada A, Takahashi H, Nagaoka I, Iwabuchi K, Mikami O, Kira S. Effect of cigarette smoke on the mRNA and protein expression of carcinoembryonic antigen (CEA), a possible chemoattractant for neutrophils in human bronchioloalveolar tissues. Thorax 1995; 50: 651-7.
114. Paone G, De Angelis G, Munno R, Pallotta G, Bigioni D, Saltini C, Bisetti A, Ameglio F. Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1. European Respiratory Journal. 1995; 8: 1136-40.
115. Paone G, De Angelis G, Greco S, Fiorucci F, Bisetti A, Ameglio F. Carcinoembryonic antigen, tissue polypeptide antigen and neuron specific enolase pleural levels used to classify small cell and non-small cell lung cancer patients by discriminant analysis. J Cancer Res Clin Oncol 1996; 122: 499-503.
116. Parmar MKB. Pitfalls and biases in the reporting and interpretation of the results of clinical trials. Lung Cancer 1994; 10: 143-50.
117. Parmar MKB, Machin D. Survival analysis. A practical approach. John Wiley & Sons, Chichester, 1995. (ISBN 0-471-93640-5).
118. Pasini F, Pelosi G, Mostacci R, Santo A, Masotti A, Spagnolli P, Recaldin E, Cetto GL. Detection at diagnosis of tumor cells in bone marrow aspirates of patients with small-cell lung cancer (SCLC) and clinical correlations. Ann-Oncol. 1995; 6: 86-8.
119. Pastorino U. Benefits of neoadjuvant chemotherapy in NSCLC. Chest 1996; 109(5 SUPPL.): 96-101.
120. Paus E, Risberg T. Establishment and evaluation of a radioimmunoassay for neuron specific enolase. Tumor biol 1989; 10: 23-30.
121. Pearse AGE. The diffuse neuroendocrine system: Falcification and verification of a concept. In: Grossman MI, Brazier MAB, Lechago J (Eds.). Cellular basis of chemical messengers in the digestive system. Academic Press. A subsidiary of Harcourt Brace Jovanovich, Publishers, New York, London, Toronto, Sydney, San Francisco, 1981: 13-6.
122. Peshavaria M, Quinn GB, Reeves I, Hinks LJ, Day INM. Molecular biology of the human enolase gene family: nerve(γ), muscle (β) and general (α) isoforms. Biochem Soc Transact 1990; 18: 254-5.
123. Pharmacia RIA kit. Radioimmunoassay kit. Kabi Pharmacia Diagnostics AB, Uppsala, Sweden, 1992.
124. Pignon JP, Arriagada R, Ihde D, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B, Onoshi T, Østerlind K, Tattersall MHN, Wagner H. A meta-analysis of thoracic radiotherapy for small cell lung cancer. Eng J Med 1992; 327: 1628-4.
125. Pinson P, Joos G, Watripont P, Brusselle G, Pauwels R. Serum neuron specific enolase as a tumor marker in the diagnosis and follow up of small cell lung cancer. Respiration. 1997; 64: 102-7.
126. Plebani M, Basso D, Navaglia F, De Paoli M, Tommasini A, Cipriani A. Clinical evaluation of seven tumour markers in lung cancer diagnosis: Can any combination improve the results? British Journal of Cancer 1995; 72: 170-3.
127. van de Pol M, Twijnstra A, ten Velde GP, Menheere PP. Neuron specific enolase as a marker of brain metastasis in patients with small cell lung carcinoma. J Neurooncol 1994; 19: 149-54.
128. Polak JM, Becker KL, Cutz BE, Gail DB, Goniakowska-Witalinska L, Gosney JR, Lauweryns JM, Linnoila I, McDowell EM, Miller YE, Scheuermann DW, Springall DR, Sunday ME, Zaccone G. Lung endocrine cell markers, peptides, and amines. Anatol Rec 1993; 236: 169-71.
129. Prentø P, Jørgensen LGM. Application of direct or coupled enolase kinetic assays in clinical biochemistry. J Tumor Marker Oncol 1996; 11(4): 29-34.
130. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer: A meta-analysis. Ann Intern Med 1996; 125: 723-9.
131. Pahlman S, Esscher T, Berg J, Steinholtz, Nöu E, Nilson K. Neuron specific enolase as a marker for neuroblastoma and small cell carcinoma of the lung. Tumour Biol 1984; 5: 119-26.
132. Quoix E, Charloux A, Popin E, Pauli G. Inability of serum neuron-specific enolase to predict disease extent in small cell lung cancer. Eur J Cancer 1993; 29: 2248-50.
133. Rapellino M, Pecchio F, Arosio C, Coni F, Revello F, Baldi S, Scappaticci E, Libertucci D, Obert R, Pagni R, Cellerino A. NSE and CEA determination in serum of patients with small cell lung cancer. J Nuclear Med Allied Sci 1990; 34: 147-9.
134. Ratto GB, Mereu C, Rovida S. Multiple tumour markers for diagnosis, management and follow-up of potentially resectable lung cancer. Panminerva Medica 1993; 35: 186-92.
135. Rawson NSB, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990; 61: 597-604.
136. Sagman U, Feld R, Evans WK, Warr D, Shepherd FA, Payne D, Pringle J, Yeoh J, DeBoer G, Malkin A, Ginsberg R. The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small cell lung cancer. J Clin Oncology 1991; 9: 954-61.
137. Sarandakou A, Poulakis N, Rizos D, Trakakis E, Phocas I. Soluble interleukin-2 receptors (sIL-2R) and neuron specific enolase (NSE) in small cell lung carcinoma. Anticancer Res 1993; 13: 173-5.
138. Schiller JH. Topotecan in small cell lung cancer. Lung Cancer 1997; 18 Suppl 2:26.
139. Schwartz MK. Enzymes as prognostic markers and therapeutic indicators in patients with cancer. Clin Chim Acta 1992; 206: 77-82.
140. Schwartz MK. Current status of tumour markers. Scnd J Clin & Lab Invest 1995a; 55(Supp211): 5-14.
141. Schwartz MK. Acute phase reactants as tumor markers. Cancer Invest 1995b; 13: 444-5.
142. Sculier JP, Feld R, Evans WK, Shepherd FA, DeBoer G, Malkin DG, Malkin. Carcinoembryonic antigen: A Useful prognostic marker in small cell lung cancer. J Clin Oncol 1985; 3: 1349-54.
143. Sehested M, Hirsch FR, Østerlind K, Olsen JE. Morphological variations of small cell lung cancer. Cancer 1986; 57: 804-7.
144. Sell S, Garrett CT. Clinical application of genetic, oncogenic, and differentiation markers of cancer. In Garrett CT & Sell S, Eds., Cellular cancer markers. Humana Press Inc. Totowa, New Jersey, 1995: 1-16. (ISBN 0-89603-210-8).
145. Seregni E, Botti C, Bogni A, Bombardieri E. Tumour marker evaluation in patients with lung cancer. Scandinavian Journal of Clinical and Laboratory Investigation. 1995; 55 (Suppl. 221): 67-71.
146. O'Shea P, Cassidy M, Freaney R, McCarthy P, Fennelly J. Serum neuron specific enolase and immunohistochemical markers of neuroendocrine differentiation in lung cancer. Ir J Med Sci. 1995; 164: 31-6.
147. Sheppard MN, Corrin B, Bennett MH, Marangos PJ, Bloom SR, Polak JM. Immunocytochemical localization of neuron specific enolase in small cell carcinomas and carcinoid tumours of the lung. Histopathology 1984; 8: 171-81.
148. Shipp MA and 27 others. A predictive model for aggressive non-hodgkin lymphoma. The international non-hodgkin lymphoma prognostic factors project. NEJM 1993; 328, 987-94.
149. Silverman WF. Neuron specific enolase reflects metabolic activity in mesencephalic neurons of the rat. Brain Res 1992; 577: 276-84.
150. Simko V. Alkaline phosphatase in biology and medicine. Dig Dis 1991; 9: 189-209
151. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994; 69: 979-85.
152. Siu LL, Shepherd FA, Murray N, Feld R, Pater J, Zee B. Influence of age on the treatment of limited-stage small-cell lung cancer. Journal of Clinical Oncology 1996; 14: 821-8.
153. Skov BG, Sørensen JB, Hirsch FR, Larsson L-I, Hansen HH. Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. Ann Oncol 1991; 2: 355-60.
154. Skov BG, Hirsch FR, Bobrow L. Monoclonal antibodies in the detection of bone marrow metastases in small cell lung cancer. Br J Cancer 1992; 65: 593-6.
155. Smith KD, Elliott MA, Elliott HG, McLaughlin M, Wightman P, Wood GC. Heterogeneity ofalpha-1-acid glycoprotein in rheumatoid arthritis. J Chromatography 1994; 661: 7-14.
156. Smyth JF. Docetaxel in small cell lung cancer. Lung Cancer 1997; 18 Suppl 2: 27.
157. Sørensen JB. How valuable is response as prognostic criterium in non-small cell lung cancer? Lung Cancer 1991; 7: 253-7.
158. Sørensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 1993; 67: 773-5.
159. Souhami RL, Bradbury I, Geddes DM, Spiro SG, Harper PG, Tobias JS. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 1985; 45: 2878-82.
160. Splinter TAW, Cooper EH, Kho GS, Oosterom R, Peake MD. Neuron specific enolase as a guide to the treatment of small cell lung cancer. Eur J Cancer Clin Oncol 1987a; 23: 171-6.
161. Splinter TAW, Cooper EH, Oosterom R, Peake MD, Brown DA. Doubling time of neuron specific enolase and survival in small cell lung cancer patients. Results of a preliminary analysis. Eur J Resp Dis Supp 1987b; 70: 37-44.
162. Splinter TAW, Carney DN, Teeling M, Oosterom R. Levels of neuron specific enolase after chemotherapy do not predict a response in small cell lung cancer. J Cancer Res Clin Oncol 1988; 114: 641-3.
163. Splinter TA, Carney DN, Teeling M, Peake MD, Kho GS, Oosterom R, Cooper EH. Neuron-specific enolase can be used as the sole guide to treat small-cell lung cancer patients in common clinical practice. J Cancer Res Clin Oncol 1989; 115: 400-1.
164. Stieber P, Dienemann H, Hasholzner U, Mueller C, Poley S, Hofmann K, Fateh Moghadam A. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide aspecific antigen (TPS) as tumour markers in lung cancer. Eur J Clin Chem Clin Biochem 1993a; 31: 689-94.
165. Stieber P, Hasholzner U, Bodenmuller H, Nagel D, Sunder Plassmann L, Dienemann H, Meier W, Fateh Moghadam A. CYFRA 21-1. A new marker in lung cancer. Cancer 1993b; 72: 707-13.
166. Sundaresan V, Reeve JG, Stenning S, Stewart S, Bleehen NM. Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours. Br J Cancer 1991; 64: 333-8.
167. Suresh MR. Classification of tumor markers. Anticancer Res 1996; 16: 2273-8.
168. Szturmowicz M, Roginska E, Roszkowski K, Kwiek S, Filipecki S, Rowinska-Zakrzewska E. Prognostic value of neuron specific enolase in small cell lung cancer patients. Lung Cancer 1993; 8: 259-4.
169. Szturmowicz M, Sakowicz A, Remiszewski P, Szopiñski H, Wasowska H, Zych J, Rowiñska-Zakrzewska E. The role of serum neuron specific enolase monitoring for evaluation of treatment results and prognosis in small cell lung cancer patients. J Tumor Marker Oncology 1996; 11(4): 23-8.
170. Takei N, Kondo J, Nagaike K., Ohsawa K, Kato K, Kohsaka S. Neuronal survival factor from bovine brain is identical to neuron-specific enolase. J Neurochem 1991; 57: 1178-84.
171. Tapia FJ, Polak JM, Barbosa AJA, Bloom SR, Marangos PJ, Dermody C. Neuron-specific enolase is produced by neuroendocrine tu-mours. Lancet 1981; 1:808-11.
172. Turrisi AT. Combined platinum etoposide with radiation therapy in limited stage small cell lung cancer: an effective treatment strategy. Lung Cancer 1995; 12 Suppl: 41-51.
173. Wagenaar SS, Tazelaar HD. Ten years after the WHO classification for lung cancer: where are we? Lung Cancer 1994; 11 Suppl. 3: 39-43.
174. Wajchenberg BL, Mendonca B, Liberman B, Adelaide M, Pereira A, Kirschner MA. Ectopic ACTH syndrome. J Steroid Biochem Mol Biol. 1995; 53: 139-51.
175. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10: 890-5.
176. Werner M, Ballo M, James G. Comparative clinical evaluation of biochemical and genomic tumour marker. Clin Chim Acta 1993; 217: 39-55.
177. Weynants P, Humblet Y, Canon JL, Symann M. Biology of small cell lung cancer: an overview. Eu Respir J. 1990; 3: 699-714.
178. Wielders JP, Bartels CT, Bank CM, Meek JC, van Dieijen Visser MP, Brombacher PJ. The diagnostic value of neuron-specific enolase and carcinoembryonic antigen analyses in patients with carcinoma of the lung. J Clin
179. Vincent MD, Ashley SE, Smith IE. Prognostic factors in small cell lung cancer: A simple prognostic index is better than conventional staging. Eur J Cancer Clin Oncol 1987; 23: 1589-99.
180. Vollmer RT, Birch R, Ogden L, Crissman JD. Subclassification of small cell cancer of the lung: The southeastern cancer study group experience. Human Pathol 1985; 16: 247-52.
181. Work E, Nielsen OS, Bentzen SM, Fode K, Palshof T. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited stage small cell lung cancer. J Clin Oncol 1997; 15: 3030-3037.
182. World Health Organization. Histological Typing of Lung Tumours. 2nd edition. Inter-national Histological Classification of Tu-mours. No 1, Geneva 1981.
183. World Health Organization. Handbook for reporting results of cancer treatment. World Health Organization, Geneva, 1979 & 1982.
184. Zandwijk N van, Jassem E, Bonfrer JMG, Tinteren H van. Value of neuron specific enolase in early detection of relapse in small cell lung carcinoma. Eur J Cancer 1990; 26: 373-6.
185. Zandwijk N van, Mooi WJ, Rodenhuis S. Prognostic factors in N-SCLC. Recent experiences. Lung Cancer 1995; 12 Suppl 1: 27-33.
186. Zelen M. Keynote address on biostatics and data retrieval. Cancer Chemother Rep. (part 3), 1973; 4: 31-42.
187. Østerlind K, Ihde DC, Ettinger DS, Gralla RJ, Karrer K, Krauss S, Maurer LH, Rorth M, Sorenson S, Vincent R. Staging and prognostic factors in small cell carcinoma of the lung.Cancer Treat Rep 1983; 67: 3-9.
188. Østerlind K, Andersen PK. Prognostic factors in small cell lung cancer: Multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986a; 46: 4189-94.
189. Østerlind K, Pedersen AG, Vindeløv L, Sörenson S, Hansen M, Dombernowsky P, Hansen HH. Alternating or continuos chemotherapy of extensive stage small cell lung cancer. Lung Cancer 1986; 2: 127-8.
190. Østerlind K, Hansen HH, Dombernowsky P, Hansen M, Andersen PK. Determinants of complete remission and maintenance in chemotherapy with or without irradiation of small cell lung cancer. Cancer Res 1987; 47: 2733-6.